S**S
发帖数: 120 | 1 【 以下文字转载自 Boston 讨论区 】
发信人: SURS (SURS), 信区: Boston
标 题: 2012 CABA Regulatory Training Program 本地学员报名开始
关键字: Regulatory， Training， pharmace
发信站: BBS 未名空间站 (Sat Sep 22 09:31:08 2012, 美东)
这是 CABA (美中医药协会）第四期招生,招收八名本地学员。有关收费询问，请联系我。
Who Should Attend:
Professionals in transition to a Regulatory Affair career; professionals
needing interactions with China FDA; pharmaceutical & biotech entrepreneurs
to be specialized in China & US regulations...
2012 CABA Regulatory Training Program
Continued on the success of the 2009, 2010, and 2011 pharmaceutical/Biologic
/Medical Device Regulatory Training programs for the Wuhan Food and Drug
Administration, the 2012 Pharmaceutical/Biologic/Medical Device Regulatory
Training program is again designed to focus on training in regulatory
affairs in biotechnology, pharmaceuticals, medical device as well as
clinical project management, drug development perspectives,
commercialization, and post-marketing safety management. Courses will be
offered in a variety of formats including seminars, lectures, discussion,
and site visits to FDA, local professional organizations, and biotechnology/
pharmaceutical companies as well as pharmacy stores. CABA will collaborate
with organizations including Massachusetts Biotechnology Council (MassBio),
Massachusetts Medical Device Industry Council (MassMEDIC) and Massachusetts
Life Science Center among others. The training program will also take
advantage of resources at Boston area universities and research institutes
including Harvard Medical School, Massachusetts College of Pharmacy and
Health Sciences, and Northeastern University as well as global
pharmaceutical and biotechnology companies such as Pfizer, Novartis,
AstraZeneca, Amgen, Biogen, Genzyme, Merck, Shire, Siemens, Boston
Scientific, etc.
What: CABA 2012 Regulatory Training Program, enrolling 8 local trainees
When: Sept 18 - Dec 12, 2012
Where: Lectures - Quality Inn, Lexington, MA; Site Visit - multiple
companies & organizations
For fees and more details, please contact me.
Thanks! |
|
